--- title: "DSIP Peptide: Benefits, Dosage, Side Effects & Sleep" description: "DSIP, delta sleep-inducing peptide, explained: what the human sleep trials found, why deep sleep did not change, how it may work, side effects and safety." canonical: "https://www.vitalsvault.com/peptides/dsip" last-updated: 2026-08-22 --- # DSIP Peptide: Benefits, Dosage, Side Effects & Sleep > DSIP, delta sleep-inducing peptide, explained: what the human sleep trials found, why deep sleep did not change, how it may work, side effects and safety. ![A woman in her mid forties sleeps peacefully under a white duvet, early blue morning light through linen curtains, one hand under the pillow](https://www.vitalsvault.com/_next/image?url=%2Fpublic-v3%2Fshoot%2Fpeptides%2Fpep-dsip.webp&w=3840&q=75&dpl=shadow-production-f0162cb4d465-40992538108-1) Peptide Guide · Brain, mood and sleep # DSIP Delta sleep-inducing peptide, emideltide DSIP was named for deep sleep before anyone showed it could deepen sleep in people. Fifty years on, that is still the open question. [Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist)[Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans) Free to join · One email when peptide care opens · Most lab results in 3–5 business days Studied forSleep, stress, withdrawal and pain EvidenceEarly human data Taken asAs prescribed by a clinician Studied forSleep, stress, withdrawal and pain EvidenceEarly human data Taken asAs prescribed by a clinician ## DSIP, in short DSIP, delta sleep-inducing peptide, is a nine-amino-acid peptide isolated from rabbit blood in Basel in 1977 and named for deep, slow-wave sleep. Small human trials in the 1980s and 1990s found weak sleep effects, and deep sleep itself did not change. It was also studied for withdrawal and pain. No receptor had been identified as of a 2006 review, and its mechanism is unknown. Medically reviewed by [Robert Lufkin, MD (opens in a new tab)](https://www.robertlufkinmd.com/) Chief Medical Officer, Vitals Vault · Updated October 29, 2026 · 13 sources ## At a glance Early human data TypeNine-amino-acid peptide; its natural occurrence and role remain uncertain[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) Discovered1977, in rabbit cerebral venous blood, in Basel[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) Studied forInsomnia, withdrawal and chronic pain in people; stroke recovery in rats[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[8](https://www.vitalsvault.com/peptides/dsip#source-larbig-1984)[10](https://www.vitalsvault.com/peptides/dsip#source-tukhovskaya-2021) ReceptorNone identified; mechanism still unresolved[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) In bloodBroken down rapidly; some analogues last longer[5](https://www.vitalsvault.com/peptides/dsip#source-graf-1987) FDA statusNot approved. Advisory committee rejected it for the compounding list (July 2026)[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa) ## Before you consider DSIP - Safety The human trials were small and short. The largest, in withdrawal, reported good tolerance apart from headaches in a few patients. FDA found no safety information for the proposed route.[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[12](https://www.vitalsvault.com/peptides/dsip#source-fda-bulks) [Side effects and safety](https://www.vitalsvault.com/peptides/dsip#safety) - Legal status Not FDA approved. FDA’s advisers rejected adding it to the compounding list in July 2026, and it is not covered by the October 2026 enforcement discretion.[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa)[12](https://www.vitalsvault.com/peptides/dsip#source-fda-bulks) [FDA status](https://www.vitalsvault.com/peptides/dsip#fda-status) - How it’s taken In the human trials it was given by intravenous injection or infusion. There is no standard US prescription form.[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa) [Forms and dosage](https://www.vitalsvault.com/peptides/dsip#how-taken) ## How does DSIP work? Nobody knows for certain how it works. These three points are the most credible. - ### No known cell target A 2006 review found no gene, parent protein or cell target for DSIP, so how it affects sleep is still a guess.[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) - ### Breaks down fast DSIP breaks down quickly in human and rat blood. Two altered versions lasted longer, which may explain mixed results.[5](https://www.vitalsvault.com/peptides/dsip#source-graf-1987) - ### Links to the opioid system Early animal work suggested it acts partly through the body’s opioid system. A drug that blocks that system dulled a memory gain in rats.[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[9](https://www.vitalsvault.com/peptides/dsip#source-roy-2018) ## DSIP benefits: what it is studied for The human evidence is old, small and mixed. The animal study is more positive but is not proof of effect in people. 1. Human study01 ### Sleep in insomnia A 1981 Lancet report described better sleep in insomniacs. Two later double-blind trials in chronic insomnia concluded the effects were weak or of little clinical significance.[2](https://www.vitalsvault.com/peptides/dsip#source-schneider-helmert-1981)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987) 2. Human study02 ### Withdrawal symptoms In an uncontrolled 1984 study of 107 inpatients in alcohol or opiate withdrawal, most improved quickly after DSIP, though anxiety eased more slowly.[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984) 3. Animal study03 ### Stroke recovery in rats In rats with induced stroke, nasal DSIP did not significantly shrink the brain injury, but animals recovered motor function faster.[10](https://www.vitalsvault.com/peptides/dsip#source-tukhovskaya-2021) ## What the research shows Early human data 1. 1 · Cells in a labNot cited This guide cites no findings at this level. Shows a mechanism 2. 2 · Animals Studied In rats with induced stroke, nasal DSIP did not significantly shrink the brain injury, but animals recovered movement faster.[10](https://www.vitalsvault.com/peptides/dsip#source-tukhovskaya-2021) Shows an effect in a body 3. 3 · People Studied Small trials in the 1980s and 1990s found weak sleep effects, and deep sleep did not change. Two double-blind trials judged the benefit weak or of little clinical value.[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987) Shows it works in people The evidence level is early human data, and most of it dates from the 1980s and 1990s. The sleep trials were small and gave inconsistent results, and the authors of two of them concluded the benefit was weak or of little clinical significance. The withdrawal and pain studies had no control groups. None of the studies cited here is a modern trial that settles the question.[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[8](https://www.vitalsvault.com/peptides/dsip#source-larbig-1984) The full guide to DSIP 8 min read · Medically reviewed by Robert Lufkin, MD ## The search for a sleep chemical in the blood Is there something in your blood that makes you sleepy? Finding out took fourteen years. A later review dates the work of isolating and characterizing a candidate from 1963 to 1977, when a group in Basel, Switzerland, reported a nine-amino-acid peptide pulled from the venous blood draining the brains of rabbits. It was named for the stage of sleep it was hoped to control, delta, the deep, slow-wave sleep of the first part of the night. The name made a promise. Delta sleep-inducing peptide, DSIP for short, sounded like the body’s own sleeping pill, and in the decade that followed it attracted a wave of research. By 1986, a review in the journal Peptides could describe work on insomnia, pain and withdrawal, alongside studies mapping DSIP-like material through the body. Then the story stalled. The same 1986 review noted that DSIP’s physiological functions and its mechanism of action remained to be established. Twenty years later, a 2006 review in the Journal of Neurochemistry was titled, plainly, a still unresolved riddle. That arc, a confident name, an early burst of studies and a long fade, is the most useful way to understand DSIP. It explains why the peptide is still discussed, and why the evidence never caught up with the name.[6](https://www.vitalsvault.com/peptides/dsip#source-graf-1986)[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) ## How DSIP works, or the riddle of the missing receptor Many signalling peptides can be traced back to a gene, a parent protein and a receptor that receives them. For DSIP, as of the 2006 review, none of the three had been found. The 2006 review called the hypothesis of DSIP as a sleep factor extremely poorly documented and still weak, largely because of that gap. DSIP is also a loner. Its structure does not resemble any known peptide family. Antibodies that recognize it light up specific hormone-making nuclei of the hypothalamus in many vertebrates, but those regions are not especially involved in sleep. The review’s authors proposed that a related, still-undiscovered peptide may explain much of what has been attributed to DSIP. A second problem is survival. In 1987, the Basel group incubated DSIP in human and rat blood and found that it was broken down quickly. Two modified versions, including a phosphorylated analogue, degraded more slowly and persisted longer. The authors raised the possibility that this explains the sometimes stronger and more consistent effects of DSIP analogues. The third thread involves opioids. Earlier animal work found that DSIP, like morphine and alcohol, induced slow-wave sleep when injected into a specific brainstem circuit, and naloxone, an opioid blocker, reversed it. A 2018 rat study found that naloxone also blunted the memory benefit of phosphorylated DSIP. These hints have never added up to a defined mechanism.[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006)[5](https://www.vitalsvault.com/peptides/dsip#source-graf-1987)[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[9](https://www.vitalsvault.com/peptides/dsip#source-roy-2018) ## DSIP for sleep: what the human trials found The high point came in 1981, when The Lancet published a short report from the Basel group titled synthetic delta-sleep-inducing peptide improves sleep in insomniacs. It was brief, early and from the team that discovered the peptide, and it set the tone for much of what followed. Independent tests followed. In 1987, a separate team gave DSIP or placebo intravenously to chronic insomniacs over four nights in a double-blind crossover design and recorded their sleep in the lab. Awakenings, time to fall asleep and time awake during the night fell, but not significantly compared with baseline or placebo nights. Total sleep rose a little, almost entirely as light stage 2 sleep, but the stage 2 difference between DSIP and placebo nights was already there at baseline. The authors concluded the improvement was of little clinical significance. In 1992, researchers at the University of Amsterdam ran a double-blind trial in 16 people with chronic insomnia, who slept five nights in the lab. Sleep efficiency was slightly higher and sleep onset slightly faster with DSIP than with placebo. On closer analysis, the effects were weak and partly reflected a chance change in the placebo group. Subjective sleep quality did not change. Their conclusion was blunt. Short-term DSIP was not likely to be of major benefit in chronic insomnia. None of the studies cited here is a later human insomnia trial that overturns it.[2](https://www.vitalsvault.com/peptides/dsip#source-schneider-helmert-1981)[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992) ## The deep-sleep peptide that left deep sleep alone The 1987 trial did more than measure total sleep. It broke the night into stages. Stages 3 and 4, the slow-wave sleep that gave delta sleep-inducing peptide its name, did not change under DSIP. REM sleep did not change either. The small gain in sleep time came from stage 2, the lighter sleep that fills much of the night, and even that difference from placebo was already present at baseline, so it is hard to credit to DSIP. The 2006 review adds a twist from animal research. In early studies by the authors’ own group in rabbits and rats, certain artificial structural analogues of DSIP significantly promoted slow-wave sleep. DSIP itself did not. A naturally occurring dermorphin-related peptide, sharing five of DSIP’s nine positions, also promoted deep sleep in rabbits. Put those findings beside the 1987 blood study, which found that analogues last longer in blood than DSIP itself, and the 2018 rat study, in which a phosphorylated analogue increased both non-REM and REM sleep at simulated high altitude. A pattern appears. The effects that match the name tend to belong to modified relatives of DSIP rather than to the original molecule. This is a hypothesis, built from a handful of small studies, and none of the studies cited here tested an analogue in people with insomnia. But it reframes the question. When people say DSIP, the evidence suggests the interesting biology may sit with sturdier cousins of the peptide, or with the undiscovered DSIP-like peptide the 2006 review proposed, and not with the nine amino acids sold under the name.[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006)[5](https://www.vitalsvault.com/peptides/dsip#source-graf-1987)[9](https://www.vitalsvault.com/peptides/dsip#source-roy-2018) ## DSIP for withdrawal and chronic pain The opioid link inspired a second line of human work. If DSIP acted like morphine and alcohol in that brainstem circuit, perhaps it could ease withdrawal from them. In 1984, a clinical team gave DSIP intravenously to 107 inpatients, 47 in alcohol withdrawal and 60 in opiate withdrawal. Among those who could be evaluated, symptoms disappeared or improved markedly and rapidly in 97 percent of opiate patients and 87 percent of alcohol patients, according to physicians and nurses. Anxiety eased more slowly. Tolerance was good, apart from headaches in a few patients. There was, however, no control group, and withdrawal symptoms naturally fade with time and care. The same issue of European Neurology carried a pilot study in 7 people with chronic, severe pain, including migraine, vasomotor headache, chronic tinnitus and psychogenic pain attacks. Pain levels fell significantly in 6 of the 7 compared with their own earlier records, and depressive symptoms eased too. Results like these are why DSIP drew interest beyond sleep, and why that interest faded. Uncontrolled studies in a few dozen or a hundred people can only suggest. None of the studies cited here is a controlled trial that confirms them.[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[8](https://www.vitalsvault.com/peptides/dsip#source-larbig-1984) ## What newer animal studies suggest Interest in DSIP did not end in the 1990s, but it moved back to the lab. In 2018, researchers in Delhi exposed rats to simulated high altitude, where oxygen is scarce and sleep falls apart. A phosphorylated form of DSIP improved both non-REM and REM sleep and restored memory in the water maze, along with a memory-linked signalling protein in the hippocampus called CREB. In 2021, a Russian team gave rats DSIP through the nose before and after an induced stroke. The damaged area of brain was smaller in treated animals, though not significantly. Motor coordination on a rotating rod recovered significantly faster. Both studies are interesting, and both are in rats under extreme conditions. Neither tells us what DSIP does for an ordinary adult who sleeps badly, which is the question most readers actually have. They also share a limit. Each tested one model in one lab, and neither result has been repeated by another group in the studies reviewed here. Encouraging rat results often fade in people, and DSIP’s own history, from the confident 1981 report to the weak 1992 trial, is a small example of exactly that.[9](https://www.vitalsvault.com/peptides/dsip#source-roy-2018)[10](https://www.vitalsvault.com/peptides/dsip#source-tukhovskaya-2021) Know your baseline before any peptide 120+ lab tests at Quest Diagnostics, every result reviewed by a licensed clinician. Most results in 3–5 business days. A baseline today gives your clinician something to compare against if you start DSIP later. [Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans)[Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist) Full refund before your blood draw · No membership ## What we actually know in people The human record is a set of small studies from roughly 1981 to 1992. Two controlled insomnia trials, with 16 people in one, found weak effects or effects of little clinical significance. Two uncontrolled studies, in 107 withdrawal patients and 7 pain patients, reported striking improvement without a comparison group. That pattern is common in medicine. Open studies look strong, and controlled studies shrink the effect. For DSIP, the controlled evidence points to small, inconsistent changes in sleep and no change in the deep sleep the peptide was named for. None of the studies cited here revisits it with current methods. It also helps to look at who ran which study. The 1981 Lancet report and the 1987 blood-stability work came from the Basel group that discovered DSIP. The two double-blind insomnia trials came from separate teams, and they found the weakest effects. On its own, that pattern proves nothing about bias. It is still a good reason to want replication before trusting the early results.[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[8](https://www.vitalsvault.com/peptides/dsip#source-larbig-1984) ## DSIP side effects and safety Most DSIP studies were too short and small to define a safety profile. The largest, the 1984 withdrawal study, reported good tolerance with headaches in a few patients. The sleep trials, run over a few nights, focused on sleep measures rather than side effects. FDA’s April 2026 compounding safety page lists emideltide, the generic name for DSIP. It states that FDA found no safety information for the proposed route and notes risks from immunogenicity, an immune reaction to the peptide, and from peptide-related impurities. The 1987 blood study showed DSIP breaks down quickly once it is in blood. Separately, nothing in the research cited here tested what vials sold online actually contain, so identity, purity and strength are unknown. People taking sedatives or opioids, or in recovery from alcohol or opioid use, should not experiment with a peptide studied partly for its links to the opioid system.[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[12](https://www.vitalsvault.com/peptides/dsip#source-fda-bulks)[5](https://www.vitalsvault.com/peptides/dsip#source-graf-1987) ## Labs that find the reasons behind poor sleep If you are reading about DSIP, you probably sleep badly. A clinician’s assessment comes first, and some contributors can show up on a blood test. TSH screens the thyroid, because an overactive gland produces light, restless sleep. Cortisol is worth checking only when an adrenal problem is suspected, since one morning reading cannot describe your daily rhythm or explain insomnia. Ferritin measures iron stores. Low ferritin is linked with restless legs, an urge to move the legs at night that breaks up sleep. Red-cell magnesium gives a partial read of a mineral involved in nerve and muscle function. None of these is a DSIP marker, and an abnormal result does not by itself prove the cause of poor sleep, but thyroid disease and low iron are common, treatable contributors. This is how Vitals Vault approaches sleep and peptide care. A blood panel at Quest Diagnostics comes first, and a licensed clinician reviews your results and history before discussing options. Since DSIP is not available through compounding, finding the treatable cause is the most direct route to better sleep.[12](https://www.vitalsvault.com/peptides/dsip#source-fda-bulks)[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa) ## Is DSIP FDA approved? Where it stands in 2026 DSIP, listed by FDA as emideltide, is not FDA-approved for any use. In July 2026, FDA’s Pharmacy Compounding Advisory Committee voted against adding it to the 503A bulks list, and it is not one of the six peptides covered by the October 29, 2026 enforcement discretion. That leaves no standard US prescription route. Vials sold online as research use only are not made for people.[12](https://www.vitalsvault.com/peptides/dsip#source-fda-bulks)[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa) ## What this means for you DSIP is a peptide with a memorable name, a 1977 discovery story and a human record that never matched either. Its controlled sleep trials found weak effects, the 1987 trial found no change in deep sleep, and the most sleep-like effects in animals came from modified analogues. If sleep is the problem, the better first question is what is breaking it up. Light, timing, stress, iron and thyroid are all measurable. And if a peptide comes up, ask which molecule the evidence was actually about.[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) Know your baseline before any peptide 120+ lab tests at Quest Diagnostics, every result reviewed by a licensed clinician. Most results in 3–5 business days. A baseline today gives your clinician something to compare against if you start DSIP later. [Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans)[Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist) Full refund before your blood draw · No membership ## What to expect with DSIP In the human sleep trials, any changes appeared within a few nights of treatment and were small. The withdrawal study described rapid improvement, but without a control group it is impossible to separate DSIP from natural recovery. A responsible path for poor sleep starts with a clinician and a sleep history, with labs such as thyroid or ferritin where they fit. Because DSIP is not FDA-approved or available through compounding, the treatable causes are where most of the gains are.[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa) ## Key DSIP studies - Schneider-Helmert et al., 1981[2](https://www.vitalsvault.com/peptides/dsip#source-schneider-helmert-1981) Clinical report (The Lancet) · People with insomnia Reported better sleep with synthetic DSIP Limits: Short report by the discovering group; methods and size not in the indexed record - Dick et al., 1984[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984) Uncontrolled clinical study · 107 inpatients in alcohol or opiate withdrawal Symptoms improved rapidly in most evaluable patients; headaches in a few Limits: No control group; clinician ratings - Larbig et al., 1984[8](https://www.vitalsvault.com/peptides/dsip#source-larbig-1984) Pilot study · 7 people with chronic pain Pain fell in 6 of 7 compared with their own baseline Limits: Tiny, uncontrolled - Monti et al., 1987[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987) Double-blind crossover trial · Chronic insomniacs, four nights each More light stage 2 sleep; no change in slow-wave or REM sleep; little clinical significance Limits: Small, short; stage 2 gap already present at baseline - Bes et al., 1992[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992) Double-blind parallel trial · 16 people with chronic insomnia Slightly better sleep efficiency and onset; no change in subjective sleep quality Limits: Small; effects partly due to placebo-group change - Kovalzon & Strekalova, 2006[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) Review · Animal and lab research No gene, protein or receptor found; analogues, not DSIP itself, promoted deep sleep in animals Limits: Mini-review; proposes a hypothesis Key studies on DSIP | Study | Design | Who | What it found | Limits | | --- | --- | --- | --- | --- | | Schneider-Helmert et al., 1981[2](https://www.vitalsvault.com/peptides/dsip#source-schneider-helmert-1981) | Clinical report (The Lancet) | People with insomnia | Reported better sleep with synthetic DSIP | Short report by the discovering group; methods and size not in the indexed record | | Dick et al., 1984[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984) | Uncontrolled clinical study | 107 inpatients in alcohol or opiate withdrawal | Symptoms improved rapidly in most evaluable patients; headaches in a few | No control group; clinician ratings | | Larbig et al., 1984[8](https://www.vitalsvault.com/peptides/dsip#source-larbig-1984) | Pilot study | 7 people with chronic pain | Pain fell in 6 of 7 compared with their own baseline | Tiny, uncontrolled | | Monti et al., 1987[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987) | Double-blind crossover trial | Chronic insomniacs, four nights each | More light stage 2 sleep; no change in slow-wave or REM sleep; little clinical significance | Small, short; stage 2 gap already present at baseline | | Bes et al., 1992[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992) | Double-blind parallel trial | 16 people with chronic insomnia | Slightly better sleep efficiency and onset; no change in subjective sleep quality | Small; effects partly due to placebo-group change | | Kovalzon & Strekalova, 2006[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) | Review | Animal and lab research | No gene, protein or receptor found; analogues, not DSIP itself, promoted deep sleep in animals | Mini-review; proposes a hypothesis | ## DSIP myths and evidence - ### DSIP increases deep sleep In a 1987 trial that broke sleep into stages, slow-wave sleep did not change; the small gain was in light stage 2 sleep, and a 1992 trial found little beyond slightly better efficiency and onset. In early animal work, DSIP analogues promoted deep sleep and DSIP itself did not.[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) - ### DSIP is a natural sleep hormone your body makes No gene, parent protein or receptor for DSIP has been found, and the review that summarized this called its role as a sleep factor extremely poorly documented.[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) - ### DSIP was proven to treat insomnia in the 1980s An early Lancet report was positive, but double-blind trials in 1987 and 1992 found effects of little clinical significance and unlikely to be of major benefit.[2](https://www.vitalsvault.com/peptides/dsip#source-schneider-helmert-1981)[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992) Know your baseline first 120+ lab tests at Quest, every result reviewed by a licensed clinician. Most results in 3–5 business days. [Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans) ## How is DSIP taken? In the human trials reviewed here, DSIP was given by intravenous injection or infusion. Because FDA’s advisers rejected adding it to the compounding list, there is no standard US prescription form.[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa) ## DSIP dosage There is no FDA-approved dose of DSIP for any use. The human trials from the 1980s and 1990s gave it by intravenous injection, dosed by body weight: in insomnia, usually once at bedtime for one to seven nights, though one trial gave it in the afternoon on three days in a row; in withdrawal, several times a day for a few days; those doses are listed in the table on this page. They are decades-old research protocols, not clinical guidance. Your clinician decides whether any use is appropriate and sets the dose.[11](https://www.vitalsvault.com/peptides/dsip#source-fda-pcac-emideltide)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992)[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984) ## Typical DSIP dosage In people, DSIP was only studied as an intravenous injection dosed by body weight. Insomnia trials mostly gave one injection at bedtime for one to seven nights (one trial gave it in the afternoon on three days in a row), and a withdrawal study gave up to six injections a day for up to six days. There is no FDA-approved dose, no human data for injection under the skin, and your clinician sets any actual dose. These are reference doses from FDA labels, studies in people and clinical practice reports, shown for education. They are not a recommendation or a prescription. Your dose, form and schedule should be set by a licensed clinician who knows your history and lab results. Already have a prescribed dose? The [peptide dosage calculator](https://www.vitalsvault.com/peptides/tools/dosage-calculator) turns it into the units to draw on an insulin syringe. - Human trial · Intravenous injection over 4 minutes 25 nmol/kg (21.3 µg/kg) Once before bedtime, on test nights[2](https://www.vitalsvault.com/peptides/dsip#source-schneider-helmert-1981)[11](https://www.vitalsvault.com/peptides/dsip#source-fda-pcac-emideltide) 6 middle-aged adults with chronic insomnia, crossover with placebo - Human trial · Intravenous injection 25 nmol/kg Once each night for four nights[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987) Adults with chronic insomnia, crossover with placebo - Human trial · Intravenous injection 25 nmol/kg Once in the afternoon for 3 days[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992) 16 adults with chronic insomnia; effects were weak - Human trial · Intravenous injection 30 nmol/kg Once each night for 7 nights[11](https://www.vitalsvault.com/peptides/dsip#source-fda-pcac-emideltide) 14 middle-aged adults with chronic insomnia (Schneider-Helmert 1987, as summarized by FDA) - Human trial · Intravenous injection 25 nmol/kg (21.4 µg/kg) Up to 6 injections a day for up to 6 days[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[11](https://www.vitalsvault.com/peptides/dsip#source-fda-pcac-emideltide) Inpatients in alcohol or opioid withdrawal, open-label Typical DSIP doses in people, by source | Source | Form | Amount | How often | Notes | | --- | --- | --- | --- | --- | | Human trial[2](https://www.vitalsvault.com/peptides/dsip#source-schneider-helmert-1981)[11](https://www.vitalsvault.com/peptides/dsip#source-fda-pcac-emideltide) | Intravenous injection over 4 minutes | 25 nmol/kg (21.3 µg/kg) | Once before bedtime, on test nights | 6 middle-aged adults with chronic insomnia, crossover with placebo | | Human trial[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987) | Intravenous injection | 25 nmol/kg | Once each night for four nights | Adults with chronic insomnia, crossover with placebo | | Human trial[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992) | Intravenous injection | 25 nmol/kg | Once in the afternoon for 3 days | 16 adults with chronic insomnia; effects were weak | | Human trial[11](https://www.vitalsvault.com/peptides/dsip#source-fda-pcac-emideltide) | Intravenous injection | 30 nmol/kg | Once each night for 7 nights | 14 middle-aged adults with chronic insomnia (Schneider-Helmert 1987, as summarized by FDA) | | Human trial[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[11](https://www.vitalsvault.com/peptides/dsip#source-fda-pcac-emideltide) | Intravenous injection | 25 nmol/kg (21.4 µg/kg) | Up to 6 injections a day for up to 6 days | Inpatients in alcohol or opioid withdrawal, open-label | ## Is DSIP right for you? A clinician makes the call. These are the questions they will ask first. ### It may suit - Adults curious about DSIP who want the cause of poor sleep investigated first - People who accept that no good evidence supports it as a sleep aid ### Talk to a clinician first if you are - Taking sleep medicine, sedatives or opioids - In recovery from alcohol or opioid use (this needs its own care team) - Living with sleep apnea or a mood disorder (these need their own care) - Pregnant or breastfeeding - Living with kidney or liver disease Vitals Vault peptide care starts with a blood panel and a licensed clinician, and ends with a retest. [Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist) ## Sleep is controlled by a network no single peptide runs Sleep depends on many things working together, and one peptide is unlikely to run them all. DSIP’s trial history shows it: small bumps in sleep appeared in one study and not the next. The places to look first are the ones that can be measured or changed, such as light, timing, stress, iron and thyroid.[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006)[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992) ### What else moves the same system 1. 01Anchor the clockMorning light and a fixed wake time are everyday ways to steady your sleep timing. 2. 02Cool, dark, quietA cool, dark, quiet bedroom is a simple place to start. 3. 03Calm the eveningA wind-down routine is worth trying before any single test or product. 4. 04Check the hidden causesLow iron stores and thyroid problems are common, testable contributors to poor sleep. ## Labs to check with DSIP A blood test before you start and a retest after shows what actually changed for you. It is how Vitals Vault approaches every treatment. 1. TestA baseline panel at Quest Diagnostics. 2. DecideA licensed clinician reviews your history and results. 3. RetestThe same markers again, side by side. [Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans) - [CortisolYour main stress hormone. A clinician may check it if an adrenal problem is suspected; one morning reading does not explain poor sleep.](https://www.vitalsvault.com/biomarkers/cortisol-total) - [TSH (thyroid)An overactive thyroid causes light, restless sleep.](https://www.vitalsvault.com/biomarkers/tsh) - [FerritinLow iron stores are linked to restless legs and broken sleep.](https://www.vitalsvault.com/biomarkers/ferritin) - [Magnesium (RBC)A mineral involved in nerve and muscle function. Blood tests give only a partial read of body stores.](https://www.vitalsvault.com/biomarkers/magnesium-rbc) ## Is DSIP FDA approved? No. DSIP, listed by FDA as emideltide, is not FDA-approved for any use. FDA’s compounding safety page lists it, noting it found no safety information for the proposed route. In July 2026 FDA’s Pharmacy Compounding Advisory Committee rejected adding emideltide to the 503A bulks list, and it is not covered by the October 2026 enforcement discretion.[12](https://www.vitalsvault.com/peptides/dsip#source-fda-bulks)[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa) ### DSIP timeline 1. 1963–1977 A Basel group works to isolate and characterize DSIP from rabbit cerebral venous blood.[6](https://www.vitalsvault.com/peptides/dsip#source-graf-1986)[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) 2. 1981 The Lancet publishes a report of synthetic DSIP improving sleep in insomniacs.[2](https://www.vitalsvault.com/peptides/dsip#source-schneider-helmert-1981) 3. 1984 Uncontrolled studies in 107 withdrawal patients and 7 chronic pain patients report improvement.[7](https://www.vitalsvault.com/peptides/dsip#source-dick-1984)[8](https://www.vitalsvault.com/peptides/dsip#source-larbig-1984) 4. 1986 A review notes that DSIP’s physiological role and mechanism remain to be established.[6](https://www.vitalsvault.com/peptides/dsip#source-graf-1986) 5. 1987 Double-blind crossover trial in chronic insomnia finds no change in deep sleep; a separate study shows DSIP degrades rapidly in blood.[3](https://www.vitalsvault.com/peptides/dsip#source-monti-1987)[5](https://www.vitalsvault.com/peptides/dsip#source-graf-1987) 6. 1992 Double-blind trial in 16 chronic insomniacs concludes DSIP is unlikely to be of major therapeutic benefit.[4](https://www.vitalsvault.com/peptides/dsip#source-bes-1992) 7. 2006 Review concludes the DSIP gene, protein and receptor are still unknown.[1](https://www.vitalsvault.com/peptides/dsip#source-kovalzon-2006) 8. April 2026 FDA’s compounding safety page lists emideltide (DSIP) and notes the absence of safety information.[12](https://www.vitalsvault.com/peptides/dsip#source-fda-bulks) 9. July 2026 FDA’s Pharmacy Compounding Advisory Committee rejects adding emideltide to the 503A bulks list.[13](https://www.vitalsvault.com/peptides/dsip#source-ncpa) ![A Latino man, 31, muscular, buzzed hair, light beard patch, gap teeth reads on a rooftop stair](https://www.vitalsvault.com/_next/image?url=%2Fpublic-v3%2Fshoot%2Fpeptides%2Ffaq-dsip.webp&w=3840&q=75&dpl=shadow-production-f0162cb4d465-40992538108-1) ## DSIP questions What is DSIP used for? DSIP is studied for sleep, and in the 1980s it was also tried for alcohol and opiate withdrawal and chronic pain. It was named for sleep, but the evidence in people is thin. It is not FDA-approved to treat any condition. What are the benefits of DSIP? Early trials in insomnia gave inconsistent results, and two double-blind studies judged the effects weak or of little clinical significance. Uncontrolled 1980s studies reported improvement in withdrawal and pain. In rats, DSIP and a phosphorylated version improved sleep, memory and motor recovery. How does DSIP work? Nobody knows. As of a 2006 review, no DSIP gene or receptor had been found, the peptide breaks down quickly in blood, and early work pointed to links with opioid pathways that were never confirmed. Does DSIP increase deep sleep? Not in the 1987 trial that reported it. In that double-blind study of chronic insomniacs, slow-wave sleep did not change; the small gains were in light stage 2 sleep, and a similar gap was already there at baseline. Early animal work found that DSIP analogues, not DSIP itself, promoted deep sleep. Does DSIP help you sleep? The evidence is weak. A 1992 double-blind trial in 16 insomniacs found small effects that the authors judged unlikely to be of major benefit. A 1981 Lancet report was more positive. What are the side effects of DSIP? Safety data are sparse. The largest study, in 107 withdrawal patients, reported good tolerance apart from headaches in a few. FDA says it found no safety information for the proposed route. What is the DSIP dosage? There is no FDA-approved dose. Human trials gave DSIP by intravenous injection, dosed by body weight: mostly at bedtime for one to seven nights in insomnia (one trial used afternoon injections on three days), or several times a day in withdrawal. The doses studied are listed in the dosage table on this page. They are decades-old protocols, not clinical guidance, and your clinician decides whether any use is appropriate and sets the dose. DSIP vs epitalon: what is the difference? Both are short peptides discussed for sleep and ageing. DSIP was isolated from rabbit blood and tested in small human insomnia trials with weak results. Epitalon is a four-amino-acid peptide designed from a pineal gland extract and studied mainly for telomeres and melatonin. Neither is FDA-approved. Is DSIP FDA approved or legal? No. DSIP (emideltide) is not FDA-approved, FDA’s advisers rejected adding it to the compounding list in July 2026, and it is not covered by the October 2026 policy. Vials sold online as "research use only" are not made for people. Can I get DSIP through Vitals Vault? Vitals Vault is opening clinician-led peptide care that starts with a blood test. Join the peptides waitlist to hear first. A licensed clinician reviews your history and labs and decides whether DSIP is right for you. ## Peptides, prescribed and measured Vitals Vault is opening peptide care that starts with your blood work, is prescribed by licensed US clinicians and ends with a retest. Join the waitlist to hear first. - Prescription only - Licensed US clinicians - Quest Diagnostics labs [Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist)[Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans) ## Keep reading [Full Peptide Guide](https://www.vitalsvault.com/peptides) - EpitalonA four-amino-acid pineal peptide studied for telomeres, melatonin and healthy aging. - SemaxA seven-amino-acid nasal peptide used in Russia for stroke, studied for memory, focus and BDNF. - SelankA seven-amino-acid peptide built on tuftsin, developed in Russia and studied for anxiety. - FDA peptide update 2026What FDA’s October 2026 decision on six peptides means for you. - CerebrolysinA mixture of peptides and amino acids from pig brain, used in some countries for stroke and dementia, with weak evidence in Cochrane reviews. ## Sources 1. 1. [Kovalzon VM, et al. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/16539679/) 2. 2. [Schneider-Helmert D, et al. Synthetic delta-sleep-inducing peptide improves sleep in insomniacs. Lancet. 1981 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/6112579/) 3. 3. [Monti JM, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/3583493/) 4. 4. [Bes F, et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/1299794/) 5. 5. [Graf MV, et al. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides. 1987 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/3628078/) 6. 6. [Graf MV, et al. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/3550726/) 7. 7. [Dick P, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/6548969/) 8. 8. [Larbig W, et al. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/6548970/) 9. 9. [Roy K, et al. Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude. Life Sci. 2018 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/30107169/) 10. 10. [Tukhovskaya EA, et al. Delta sleep-inducing peptide recovers motor function in SD rats after focal stroke. Molecules. 2021 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/34500605/) 11. 11. [FDA. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23 to 24, 2026: Emideltide-related bulk drug substances (opens in a new tab)](https://www.fda.gov/media/193344/download) 12. 12. [FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (current as of April 22, 2026) (opens in a new tab)](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) 13. 13. [NCPA. FDA grants enforcement discretion for compounding six peptides. October 29, 2026 (opens in a new tab)](https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides) Written by the Vitals Vault editorial team, medically reviewed by Robert Lufkin, MD, and updated October 29, 2026. This is general education, not medical advice. None of these peptides is FDA-approved to diagnose, treat, cure or prevent any disease, and compounded medicines are not FDA-reviewed for safety, effectiveness or quality. Talk to a licensed clinician before starting any treatment. --- Canonical HTML: https://www.vitalsvault.com/peptides/dsip - [llms.txt](https://www.vitalsvault.com/llms.txt) - [sitemap.xml](https://www.vitalsvault.com/sitemap.xml) - [Developer portal](https://www.vitalsvault.com/developers)